Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Scholar Rock's Isembyld (apitegromab) wins FDA approval for spinal muscular atrophy following Ph3 success
Antibody, neurological, monoclonal antibody, spinal muscular atrophy, myostatin inhibitor - Read more

FDA expands Pharming's Joenja (leniolisib) label to children aged 4+ with activated phosphoinositide 3-kinase delta syndrome
Small molecule, autoimmune, PI3Kδ inhibitor, activated phosphoinositide 3-kinase delta syndrome, pediatric patients - Read more

FDA approves Telix Pharmaceuticals' Pixclara (floretyrosine F 18) for PET imaging of glioma in adults and pediatric patients
Radiopharmaceutical, cancer, PET imaging, glioma, brain cancer diagnostics - Read more

Johnson & Johnson to sell orthopedics unit DePuy Synthes to Apollo Equity Management in $20B deal
Divestiture, orthopedics, medtech, private equity, equity investment - Read more

Bio Usawa, Axmed partner to expand affordable biologic medicines access across Africa
Strategic collaboration, biosimilars, ophthalmology, digital health, manufacturing, commercialization - Read more

Vezeeta, EVA Pharma partner to expand digital care access for obesity and diabetes patients in Egypt
Strategic collaboration, obesity, diabetes, digital health, telehealth - Read more

Owkin licenses K Pro AI scientist and multimodal data to Servier to advance oncology research
Licensing deal, oncology, AI/ML, drug discovery, multimodal data - Read more

Glafabra Therapeutics, Medical College of Wisconsin sign exclusive patent license for lentiviral vector transfer plasmid technology
Licensing deal, rare disease, gene therapy, manufacturing, lentiviral vector - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

Johnson & Johnson's Rybrevant (amivantamab) achieves longest overall survival in Ph3 trial for EGFR exon 20 insertion-positive non-small cell lung cancer
Antibody, cancer, bispecific antibody, non-small cell lung cancer, EGFR exon 20 insertion, combination therapy - Read more

Teitur Trophics reports positive Ph1 data for TT-P34 (TT-P34) targeting lysosomal pathway in Parkinson's disease
Protein therapy, neurological, peptide, Parkinson's disease, mitochondrial dysfunction, lysosomal pathway - Read more

Definium Therapeutics' DT120 (lysergic acid diethylamide) meets Ph3 primary endpoint for generalized anxiety disorder, advancing toward FDA submission
Small molecule, neurological, LSD, generalized anxiety disorder, psychedelic therapy - Read more

Cullinan Therapeutics, Taiho Oncology's (zipalertinib) combo shows 6-month survival benefit in Ph3 epidermal growth factor receptor exon 20 insertion mutation-positive non-small cell lung cancer
Small molecule, cancer, tyrosine kinase inhibitor, non-small cell lung cancer, EGFR exon 20 insertion, combination therapy - Read more

GSK, Hansoh Pharmaceutical's (risvutatug rezetecan) cuts death risk 54% in Ph3 relapsed small-cell lung cancer trial
Antibody-drug conjugate, cancer, small cell lung cancer, B7-H3 target, second-line treatment - Read more

BioNTech's (gotistobart) shows 18.5-month median overall survival in Ph3 relapsed metastatic squamous non-small cell lung cancer
Antibody, cancer, monoclonal antibody, non-small cell lung cancer, CTLA-4, immune checkpoint inhibitor - Read more

GSK plans FDA label expansion bid for Jideytro (zidesamtinib) in first-line ROS1-positive non-small cell lung cancer
Small molecule, cancer, tyrosine kinase inhibitor, non-small cell lung cancer, ROS1 - Read more

Roche, MediLink's (tambotatug pelitecan) B7-H3 antibody-drug conjugate hits Ph3 primary endpoint in small cell lung cancer
Antibody-drug conjugate, cancer, small cell lung cancer, B7-H3, ADC safety - Read more

Summit Therapeutics, Akeso's ivonescimab cuts death risk 27% versus Keytruda in Ph3 front-line non-small-cell lung cancer
Antibody, cancer, bispecific antibody, non-small cell lung cancer, PD-1/VEGF, pembrolizumab - Read more

AstraZeneca's Tagrisso (osimertinib) shows 47–48% death risk reduction at eight-year Ph3 follow-up in early-stage epidermal growth factor receptor-mutated non-small cell lung cancer
Small molecule, cancer, EGFR inhibitor, non-small cell lung cancer, adjuvant therapy, overall survival - Read more

Shennon Biotechnologies raises $12M, advancing T-cell engager programs toward clinical development
Immuno-oncology, T-cell engager, AI/ML platform, antibody, preclinical - Read more

Athernal Bio receives £700K ($946.9K) Innovate UK grant to expand operations and R&D efforts
Cancer interception, immunotherapy, hematology, preclinical - Read more

Novo Nordisk rebrands to Novo, repositions amid GLP-1 market struggles against Eli Lilly
Small molecule, metabolic disease, strategic, competitive, financial - Read more

GE HealthCare to acquire Sofie Biosciences for up to $1B, boosting pharma diagnostics business
Radiopharmaceutical, oncology, major transaction, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

AstraZeneca's Etcamah (camizestrant) Ph3 trial fails in frontline estrogen receptor-positive, HER2-negative advanced breast cancer
Small molecule, cancer, oral SERD, breast cancer, ESR1 mutation, CDK4/6 inhibitor - Read more

AstraZeneca, Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) Ph3 data show survival concerns in first-line HER2-mutant non-small cell lung cancer
Antibody-drug conjugate, cancer, non-small cell lung cancer, HER2, Enhertu, combination therapy - Read more

GSK to close Dresden vaccine manufacturing facility by mid-2027, affecting 640 workers
Vaccine manufacturing, infectious disease, operational, cost reduction - Read more

FDA delays decision on Exelixis's zanzalintinib (zanzalintinib) plus Roche's Tecentriq for metastatic colorectal cancer to March 2027
Small molecule, cancer, kinase inhibitor, colorectal cancer, combination therapy, PD-L1 - Read more

Cellectis scraps allogeneic CAR-T programs lasme-cel and eti-cel amid in vivo competition surge
Allogeneic CAR-T, oncology, strategic, competitive, cost reduction - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here